Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Combined assessment of DYRK1A, BDNF and homocysteine levels as diagnostic marker for Alzheimer’s disease

20 Jun 2017

Abstract excerpt

Early identification of Alzheimer's disease (AD) risk factors would aid development of interventions to delay the onset of dementia, but current biomarkers are invasive and/or costly to assess. Validated plasma biomarkers would circumvent these challenges. We previously identified the kinase DYRK1A in plasma. To validate DYRK1A as a biomarker for AD diagnosis, we assessed the levels of DYRK1A and the related...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Dementia and Cognitive Impairment Research
Share to Down syndrome and intellectual disability research
Share to Frailty in Older Adults

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 28632203
DOI: 10.1038/tp.2017.123

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Combined assessment of DYRK1A, BDNF and homocysteine levels as diagnostic marker for Alzheimer’s diseasePMID 28632203Read ↗

Plasma DYRK1A as a novel risk factor for Alzheimer’s diseaseSemantic proximity Read ↗

DYRK1A Inhibitors and Perspectives for the Treatment of Alzheimer's DiseaseSemantic proximity Read ↗

The Omnipresence of DYRK1A in Human DiseasesSemantic proximity Read ↗

Precision Stratification: Kinase Assay in Asian <i>LRRK2</i> Risk Carriers and Idiopathic Parkinson DiseaseSemantic proximity Read ↗

Recent Advances in the Design, Synthesis, and Biological Evaluation of Selective DYRK1A Inhibitors: A New Avenue for a Disease Modifying Treatment of Alzheimer’s?Semantic proximity Read ↗

The Current State-of-the Art of LRRK2-Based Biomarker Assay Development in Parkinson’s DiseaseSemantic proximity Read ↗

Discovering a novel dual specificity tyrosine-phosphorylation-regulated kinase 1A (DYRK1A) inhibitor and its impact on tau phosphorylation and amyloid-β formationSemantic proximity Read ↗

APOE4 genotype is associated with CSF activated PKR levels in patients with Alzheimer's diseaseSemantic proximity Read ↗

Inhibition of discoidin domain receptor (DDR)-1 with nilotinib induces autophagy and reduces inflammation and vascular fibrosis in Alzheimer’s diseaseSemantic proximity Read ↗

Pharmacodynamic Biomarkers for Emerging LRRK2 TherapeuticsSemantic proximity Read ↗

GSK-3β, FYN, and DYRK1A: Master Regulators in Neurodegenerative PathwaysSemantic proximity Read ↗

Genetic association of neurotrophic tyrosine kinase receptor type 2 (NTRK2) With Alzheimer's disease.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.